Tackling the Spectrum of Symptom Domains in Schizophrenia: Tailoring Treatment to Address Patient Needs

Tackling the Spectrum of Symptom Domains in Schizophrenia: Tailoring Treatment to Address Patient Needs

On-Demand Webcast

Leslie Citrome, MD, MPH
Clinical Professor of Psychiatry and Behavioral Science
New York Medical College
Valhalla, New York

Christoph Correll, MD
Professor of Psychiatry and Molecular Medicine
Hofstra Northwell School of Medicine
Hempstead, New York
Medical Director, Recognition and Prevention Program
The Zucker Hillside Hospital, Northwell Health
Glen Oaks, New York

For full faculty bios, please call 609-371-1137.



This activity is intended for psychiatrists, primary care physicians, psychologists, physician assistants, psychiatric nurses, and other healthcare professionals who seek to improve the care of patients with mental health disorders.


After completing this activity, participants should be able to:

  • Explain the effect of schizophrenia symptom domains on patient quality of life, treatment outcomes, and caregiver burden
  • Describe the impact of receptor pharmacology on treatment efficacy, tolerability, and mood symptoms
  • Identify the limits of conventional schizophrenia pharmacotherapies in addressing the spectrum of symptom domains and tolerability
  • Apply clinical data regarding newer antipsychotic agents into individualized treatment plans that consider patient needs and symptom domains, treatment tolerability and adverse effects, and adherence issues

To be eligible for documentation of credit, participants must participate in the full activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: 12/21/2017
Expiration Date: 12/21/2018
Estimated time to complete: 1.5 hours

For questions regarding this educational activity, please call 609-371-1137.


In support of improving patient care, North American Center for Continuing Medical Education, LLC (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


NACCME designates this enduring material for a maximum of 1.50 AMA PRA Category 1.50 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This continuing nursing education activity awards 1.50 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.50 contact hours.


This continuing nursing educational activity awards up to 1.25 pharmacology hours.


North American Center for Continuing Medical Education, LLC (NACCME) is approved by the American Psychological Association to sponsor continuing education for psychologists. NACCME maintains responsibility for this program and its content.

Instructional Level: Advanced


The planning committee comprises Leslie Citrome, MD, MPH; Christoph Correll, MD; Douglas L. Noordsy, MD; Andrew Penn, RN, MS, NP, CNS, APRN-BC; and Meaghan Benci, Raquel Gaerlan, Jennifer Ilcyn, Randy Robbin, John Savage, and Kelly Sweeney.

Independent Clinical Reviewer: Douglas L. Noordsy, MD, Clinical Professor of Psychiatry & Behavioral Sciences, Stanford University School of Medicine; Director of Sports Psychiatry, Department of Psychiatry & Behavioral Sciences, Stanford University, Stanford, California

Nurse Planner: Andrew Penn, RN, MS, NP, CNS, APRN-BC, Psychiatric Nurse Practitioner, Kaiser Permanente, Redwood City, CA; Assistant Clinical Professor, University of California, San Francisco, CA


According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty reported the following:

Dr. Citrome: Consultant—Acadia, Alkermes, Allergan, Forum, IntraCellular Therapies, Janssen, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Pfizer, Shire, Sunovion, Takeda, Teva, Vanda; Speaker—Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Shire, Sunovion, Takeda, Vanda; Shareholder (and spouse)—Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer.

Dr. Correll: Advisor—Alkermes, Allergan, Bristol-Myers Squibb, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante, Medscape, Neurocrine, Otsuka, Pfizer, Sunovion, Takeda, Teva; Consultant—Alkermes, Allergan, Bristol-Myers Squibb, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante, Medscape, Neurocrine, Otsuka, Pfizer, Sunovion, Takeda, Teva; Research Grant—Takeda; Expert Testimony—Bristol-Myers Squibb, Janssen, Otsuka.

Dr. Noordsy have disclosed no relevant financial relationships with any commercial interests.

Ms. Benci, Ms. Gaerlan, Ms. Ilcyn, Mr. Robbin, Mr. Savage, and Ms. Sweeney have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The off-label or investigational use of D-Serine, glycine, sarcosine, bitopertin, adjunctive antidepressants, brain stimulation, adjunctive topiramate, and MIN-101 for the treatment of negative symptoms in schizophrenia will be discussed.


The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.


NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2017 by North American Center for Continuing Medical Education, LLC (NACCME). All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from NACCME. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.


This session is supported by an educational grant from Allergan, Inc.